Rennova Health, Inc.
RNVA
$0.00
$0.000.00%
09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
---|---|---|---|---|---|
Revenue | 113.44% | 154.54% | 234.88% | 304.37% | 262.01% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 113.44% | 154.54% | 234.88% | 304.37% | 262.01% |
Cost of Revenue | 25.11% | 39.77% | 42.93% | 27.88% | -22.29% |
Gross Profit | 263.51% | 419.83% | 18,884.48% | 403.02% | 169.39% |
SG&A Expenses | 50.27% | 37.40% | 24.86% | -3.99% | -41.35% |
Depreciation & Amortization | -23.45% | -14.02% | -22.34% | -27.07% | -41.02% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 35.16% | 36.31% | 30.26% | 7.45% | -33.40% |
Operating Income | 229.66% | 178.37% | 118.25% | 86.21% | 82.29% |
Income Before Tax | 162.40% | 189.27% | 102.98% | 41.85% | 61.41% |
Income Tax Expenses | 259.50% | 362.28% | 74.26% | 74.26% | 194.62% |
Earnings from Continuing Operations | 147.27% | 154.90% | 94.76% | 37.89% | 59.36% |
Earnings from Discontinued Operations | -114.58% | -103.94% | -100.15% | -100.17% | -100.09% |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 146.95% | 166.64% | -103.04% | -158.75% | -154.71% |
EBIT | 229.66% | 178.37% | 118.25% | 86.21% | 82.29% |
EBITDA | 272.23% | 200.29% | 126.95% | 90.18% | 84.53% |
EPS Basic | 100.00% | 100.00% | 100.00% | 99.51% | 98.73% |
Normalized Basic EPS | 100.00% | 100.00% | 100.00% | 99.24% | 99.60% |
EPS Diluted | 100.00% | 100.00% | 100.00% | 99.51% | 98.73% |
Normalized Diluted EPS | 100.00% | 100.00% | 100.00% | 99.24% | 99.60% |
Average Basic Shares Outstanding | 866.45% | 5,624.18% | 993,503.56% | 1,817,756.03% | 27,969,564.92% |
Average Diluted Shares Outstanding | 8,458.50% | 60,165.98% | 7,846,484.81% | 1,817,756.03% | 27,969,564.92% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |